{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:10:58Z","timestamp":1790212258841,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["HCP-41"],"award-info":[{"award-number":["HCP-41"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["HCP-41"],"award-info":[{"award-number":["HCP-41"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["HCP-41"],"award-info":[{"award-number":["HCP-41"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012323","name":"CSIR - Indian Institute of Chemical Biology","doi-asserted-by":"publisher","award":["OLP116"],"award-info":[{"award-number":["OLP116"]}],"id":[{"id":"10.13039\/501100012323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012323","name":"CSIR - Indian Institute of Chemical Biology","doi-asserted-by":"publisher","award":["OLP118"],"award-info":[{"award-number":["OLP118"]}],"id":[{"id":"10.13039\/501100012323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11315-2","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T03:53:36Z","timestamp":1757217216000},"page":"3949-3975","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["9-fluorenone-based synthetic sulfonamide compounds as dual inhibitors of SARS-CoV-2 Main-Protease and Papain-like Protease"],"prefix":"10.1007","volume":"30","author":[{"given":"Sudesna","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Sunnapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Rafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nittu","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan Gopal","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parasuraman","family":"Jaisankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2607-9485","authenticated-orcid":false,"given":"Umesh Prasad","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,7]]},"reference":[{"key":"11315_CR1","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen DR, Allerton CMN, Anderson AS et al (2021) An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science 374:1586\u20131593. https:\/\/doi.org\/10.1126\/science.abl4784","journal-title":"Science"},{"key":"11315_CR2","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh Y, Uehara S, Nakahara K et al (2022) Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J Med Chem 65:6499\u20136512. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00117","journal-title":"J Med Chem"},{"key":"11315_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmi.2024.09.007","volume":"31","author":"PP Ye","year":"2024","unstructured":"Ye PP, Yao BF, Yang Y et al (2024) Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial. Clin Microbiol Infect 31:101\u2013107. https:\/\/doi.org\/10.1016\/j.cmi.2024.09.007","journal-title":"Clin Microbiol Infect"},{"key":"11315_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eclinm.2023.102359","volume":"67","author":"Y Zhan","year":"2024","unstructured":"Zhan Y, Lin Z, Liang J et al (2024) Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. eClinicalMedicine 67:1\u201311. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102359","journal-title":"eClinicalMedicine"},{"key":"11315_CR5","doi-asserted-by":"publisher","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","volume":"67","author":"CMN Allerton","year":"2024","unstructured":"Allerton CMN, Arcari JT, Aschenbrenner LM et al (2024) A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19. J Med Chem 67:13550\u201313571. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c02469","journal-title":"J Med Chem"},{"key":"11315_CR6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger F, Stiller C, Schmitzov\u00e1 J et al (2021) Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 28:740\u2013746. https:\/\/doi.org\/10.1038\/s41594-021-00651-0","journal-title":"Nat Struct Mol Biol"},{"key":"11315_CR7","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/jm401712t","volume":"57","author":"YM B\u00e1ez-Santos","year":"2014","unstructured":"B\u00e1ez-Santos YM, Barraza SJ, Wilson MW et al (2014) X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. J Med Chem 57:2393\u20132412. https:\/\/doi.org\/10.1021\/jm401712t","journal-title":"J Med Chem"},{"key":"11315_CR8","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/B978-0-12-821618-7.00111-5","volume":"1","author":"R Mukherjee","year":"2022","unstructured":"Mukherjee R, Dikic I (2022) Proteases of SARS coronaviruses. Encycl Cell Biol 1:930\u2013941. https:\/\/doi.org\/10.1016\/B978-0-12-821618-7.00111-5","journal-title":"Encycl Cell Biol"},{"key":"11315_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.abf7945","volume":"372","author":"S G\u00fcnther","year":"2021","unstructured":"G\u00fcnther S, Reinke PYA, Fern\u00e1ndez-Garci\u00e1 Y et al (2021) X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 372:642\u2013646. https:\/\/doi.org\/10.1126\/science.abf7945","journal-title":"Science"},{"key":"11315_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18709-w","volume":"11","author":"A Douangamath","year":"2020","unstructured":"Douangamath A, Fearon D, Gehrtz P et al (2020) Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun 11:1\u201311. https:\/\/doi.org\/10.1038\/s41467-020-18709-w","journal-title":"Nat Commun"},{"key":"11315_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin D, Mukherjee R, Grewe D et al (2020) Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587:657\u2013662. https:\/\/doi.org\/10.1038\/s41586-020-2601-5","journal-title":"Nature"},{"key":"11315_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/ijms23010259","volume":"23","author":"G Macip","year":"2021","unstructured":"Macip G, Garcia-Segura P, Mestres-Truyol J et al (2021) A review of the current landscape of SARS-CoV-2 main protease inhibitors: have we hit the bullseye yet? Int J Mol Sci 23:259. https:\/\/doi.org\/10.3390\/ijms23010259","journal-title":"Int J Mol Sci"},{"key":"11315_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fchem.2022.876212","volume":"10","author":"DJ Calleja","year":"2022","unstructured":"Calleja DJ, Lessene G, Komander D (2022) Inhibitors of SARS-CoV-2 PLpro. Front Chem 10:1\u201320. https:\/\/doi.org\/10.3389\/fchem.2022.876212","journal-title":"Front Chem"},{"key":"11315_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01392-w","author":"C Huang","year":"2023","unstructured":"Huang C, Shuai H, Qiao J et al (2023) A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants. Signal Transduct Target Ther. https:\/\/doi.org\/10.1038\/s41392-023-01392-w","journal-title":"Signal Transduct Target Ther"},{"issue":"80-","key":"11315_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang L, Lin D, Sun X et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors. Science 368(80-):409\u2013412. https:\/\/doi.org\/10.1126\/science.abb3405","journal-title":"Science"},{"key":"11315_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18233-x","volume":"11","author":"L Fu","year":"2020","unstructured":"Fu L, Ye F, Feng Y et al (2020) Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat Commun 11:1\u20138. https:\/\/doi.org\/10.1038\/s41467-020-18233-x","journal-title":"Nat Commun"},{"key":"11315_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbrc.2023.03.043","volume":"657","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Wang W, Zeng P et al (2023) Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332. Biochem Biophys Res Commun 657:16\u201323. https:\/\/doi.org\/10.1016\/j.bbrc.2023.03.043","journal-title":"Biochem Biophys Res Commun"},{"key":"11315_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-20900-6","volume":"12","author":"SI Hattori","year":"2021","unstructured":"Hattori SI, Higashi-Kuwata N, Hayashi H, Allu SR, Raghavaiah J, Bulut H, Das D, Anson BJ, Lendy EK, Takamatsu Y, Takamune N (2021) A small molecule\u00a0compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun 12:1\u201312. https:\/\/doi.org\/10.1038\/s41467-021-20900-6","journal-title":"Nat Commun"},{"key":"11315_CR19","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin Z, Du X, Xu Y et al (2020) Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 582:289\u2013293. https:\/\/doi.org\/10.1038\/s41586-020-2223-y","journal-title":"Nature"},{"key":"11315_CR20","doi-asserted-by":"publisher","unstructured":"Tan B, Joyce R, Tan H, et al (2024) and drug resistance studies. 56:157\u2013168. https:\/\/doi.org\/10.1021\/acs.accounts.2c00735.SARS-CoV-2","DOI":"10.1021\/acs.accounts.2c00735.SARS-CoV-2"},{"key":"11315_CR21","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1021\/acs.jcim.1c00684","volume":"61","author":"A Manandhar","year":"2021","unstructured":"Manandhar A, Srinivasulu V, Hamad M et al (2021) Discovery of novel small-molecule inhibitors of SARS-CoV-2 main protease as potential leads for COVID-19 treatment. J Chem Inf Model 61:4745\u20134757. https:\/\/doi.org\/10.1021\/acs.jcim.1c00684","journal-title":"J Chem Inf Model"},{"key":"11315_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23313-7","volume":"12","author":"K Amporndanai","year":"2021","unstructured":"Amporndanai K, Meng X, Shang W et al (2021) Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat Commun 12:1\u20137. https:\/\/doi.org\/10.1038\/s41467-021-23313-7","journal-title":"Nat Commun"},{"key":"11315_CR23","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1073\/pnas.2301775120","volume":"120","author":"H Xu","year":"2023","unstructured":"Xu H, Li S, Liu J et al (2023) Bioactive compounds from Huashi Baidu decoction possess both antiviral and anti-inflammatory effects against COVID-19. Proc Natl Acad Sci 120:2017. https:\/\/doi.org\/10.1073\/pnas.2301775120","journal-title":"Proc Natl Acad Sci"},{"key":"11315_CR24","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3390\/biom14070797","volume":"14","author":"A Zag\u00f3rska","year":"2024","unstructured":"Zag\u00f3rska A, Czopek A, Fryc M, Jo\u0144czyk J (2024) Inhibitors of SARS-CoV-2 main protease (Mpro) as anti-coronavirus agents. Biomolecules 14:797. https:\/\/doi.org\/10.3390\/biom14070797","journal-title":"Biomolecules"},{"key":"11315_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-03090-9","volume":"5","author":"A Narayanan","year":"2022","unstructured":"Narayanan A, Narwal M, Majowicz SA et al (2022) Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun Biol 5:1\u201317. https:\/\/doi.org\/10.1038\/s42003-022-03090-9","journal-title":"Commun Biol"},{"key":"11315_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-06306-4","volume":"12","author":"GG Rossetti","year":"2022","unstructured":"Rossetti GG, Ossorio MA, Rempel S et al (2022) Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits. Sci Rep 12:1\u20139. https:\/\/doi.org\/10.1038\/s41598-022-06306-4","journal-title":"Sci Rep"},{"key":"11315_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut W, Lv Z, Zmudzinski M et al (2020) Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti\u2013COVID-19 drug design. Sci Adv 6:1\u201312. https:\/\/doi.org\/10.1126\/sciadv.abd4596","journal-title":"Sci Adv"},{"key":"11315_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20718-8","volume":"12","author":"Z Fu","year":"2021","unstructured":"Fu Z, Huang B, Tang J et al (2021) The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat Commun 12:1\u201312. https:\/\/doi.org\/10.1038\/s41467-020-20718-8","journal-title":"Nat Commun"},{"key":"11315_CR29","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut W, Lv Z, Zmudzinski M et al (2020) Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti\u2013COVID-19 drug design. Sci Adv 6:2940\u20132955. https:\/\/doi.org\/10.1126\/sciadv.abd4596","journal-title":"Sci Adv"},{"key":"11315_CR30","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1371\/journal.pbio.0030324","volume":"3","author":"H Yang","year":"2005","unstructured":"Yang H, Xie W, Xue X et al (2005) Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 3:e324. https:\/\/doi.org\/10.1371\/journal.pbio.0030324","journal-title":"PLoS Biol"},{"key":"11315_CR31","doi-asserted-by":"publisher","first-page":"21035","DOI":"10.1021\/jacs.2c04626","volume":"144","author":"S Mondal","year":"2022","unstructured":"Mondal S, Chen Y, Lockbaum GJ et al (2022) Dual inhibitors of main protease (MPro) and cathepsin L as potent antivirals against SARS-CoV2. J Am Chem Soc 144:21035\u201321045. https:\/\/doi.org\/10.1021\/jacs.2c04626","journal-title":"J Am Chem Soc"},{"key":"11315_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/procel\/pwac016","volume":"14","author":"Y Zang","year":"2023","unstructured":"Zang Y, Su M, Wang Q et al (2023) High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors. Protein Cell 14:17\u201327. https:\/\/doi.org\/10.1093\/procel\/pwac016","journal-title":"Protein Cell"},{"key":"11315_CR33","unstructured":"Zmudzinski M, Rut W, Olech K, et al (2020) Ebselen derivatives are very potent dual inhibitors of SARS-CoV-2 proteases - PLpro and Mpro in in vitro studies. bioRxiv 2020.08.30.273979"},{"key":"11315_CR34","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","volume":"3","author":"C Ma","year":"2020","unstructured":"Ma C, Hu Y, Townsend JA et al (2020) Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol Transl Sci 3:1265\u20131277. https:\/\/doi.org\/10.1021\/acsptsci.0c00130","journal-title":"ACS Pharmacol Transl Sci"},{"key":"11315_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.4155\/fmc-2021-0269","volume":"14","author":"LC Zhang","year":"2022","unstructured":"Zhang LC, Zhao HL, Liu J et al (2022) Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening. Future Med Chem 14:393\u2013405. https:\/\/doi.org\/10.4155\/fmc-2021-0269","journal-title":"Future Med Chem"},{"key":"11315_CR36","doi-asserted-by":"publisher","first-page":"124772","DOI":"10.1016\/j.ijbiomac.2023.124772","volume":"242","author":"B Kattula","year":"2023","unstructured":"Kattula B, Reddi B, Jangam A et al (2023) Development of 2-chloroquinoline based heterocyclic frameworks as dual inhibitors of SARS-CoV-2 MPro and PLPro. Int J Biol Macromol 242:124772. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.124772","journal-title":"Int J Biol Macromol"},{"key":"11315_CR37","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.3390\/molecules27196374","volume":"27","author":"P Kashyap","year":"2022","unstructured":"Kashyap P, Thakur M, Singh N et al (2022) In silico evaluation of natural flavonoids as a potential inhibitor of coronavirus disease. Molecules 27:6374. https:\/\/doi.org\/10.3390\/molecules27196374","journal-title":"Molecules"},{"key":"11315_CR38","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s11030-021-10198-3","volume":"26","author":"SA Amin","year":"2022","unstructured":"Amin SA, Ghosh K, Singh S et al (2022) Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery. Mol Divers 26:215\u2013228. https:\/\/doi.org\/10.1007\/s11030-021-10198-3","journal-title":"Mol Divers"},{"key":"11315_CR39","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/molecules26103002","volume":"26","author":"IM Vlad","year":"2021","unstructured":"Vlad IM, Nu\u021b\u0103 DC, Ancuceanu RV et al (2021) New o-aryl-carbamoyl-oxymino-fluorene derivatives with mi-crobicidal and antibiofilm activity enhanced by combination with iron oxide nanoparticles. Molecules 26:3002. https:\/\/doi.org\/10.3390\/molecules26103002","journal-title":"Molecules"},{"key":"11315_CR40","doi-asserted-by":"publisher","first-page":"7454","DOI":"10.1021\/ACSOMEGA.0C05996","volume":"6","author":"AC Puhl","year":"2021","unstructured":"Puhl AC, Fritch EJ, Lane TR et al (2021) Repurposing the Ebola and Marburg virus inhibitors tilorone, quinacrine, and pyronaridine. In vitro activity against SARS-CoV-2 and potential mechanisms. ACS Omega 6:7454\u20137468. https:\/\/doi.org\/10.1021\/ACSOMEGA.0C05996","journal-title":"ACS Omega"},{"key":"11315_CR41","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/j.bmcl.2016.02.087","volume":"26","author":"SR Choi","year":"2016","unstructured":"Choi SR, Larson MA, Hinrich SH, Narayanasamy P (2016) Development of potential broad spectrum antimicrobials using C2-symmetric 9-fluorenone alkyl amine. Bioorg Med Chem Lett 26:1997\u20131999. https:\/\/doi.org\/10.1016\/j.bmcl.2016.02.087","journal-title":"Bioorg Med Chem Lett"},{"key":"11315_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561\u2013566. https:\/\/doi.org\/10.1038\/nm0596-561","journal-title":"Nat Med"},{"key":"11315_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2174\/1389557043487402","volume":"4","author":"C Supuran","year":"2005","unstructured":"Supuran C, Innocenti A, Mastrolorenzo A, Scozzafava A (2005) Antiviral sulfonamide derivatives. Mini-Rev Med Chem 4:189\u2013200. https:\/\/doi.org\/10.2174\/1389557043487402","journal-title":"Mini-Rev Med Chem"},{"key":"11315_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28010051","author":"MY Moskalik","year":"2023","unstructured":"Moskalik MY (2023) Sulfonamides with heterocyclic periphery as antiviral agents. Molecules. https:\/\/doi.org\/10.3390\/molecules28010051","journal-title":"Molecules"},{"key":"11315_CR45","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1126\/science.2200122","volume":"249","author":"J Erickson","year":"1990","unstructured":"Erickson J, Neidhart DJ, VanDrie J et al (1990) Design, activity, and 2.8 \u00c5 crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 249:527\u2013533. https:\/\/doi.org\/10.1126\/science.2200122","journal-title":"Science"},{"key":"11315_CR46","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1021\/jm010887p","volume":"44","author":"J Schr\u00f6der","year":"2001","unstructured":"Schr\u00f6der J, Henke A, Wenzel H et al (2001) Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H\u20131,3,4-thiadiazine scaffold. J Med Chem 44:3231\u20133243. https:\/\/doi.org\/10.1021\/jm010887p","journal-title":"J Med Chem"},{"key":"11315_CR47","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.1039\/D1OB01618K","volume":"19","author":"S Alvi","year":"2021","unstructured":"Alvi S, Ali R (2021) An expeditious and highly efficient synthesis of substituted pyrroles using a low melting deep eutectic mixture. Org Biomol Chem 19:9732\u20139745. https:\/\/doi.org\/10.1039\/D1OB01618K","journal-title":"Org Biomol Chem"},{"key":"11315_CR48","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1021\/jm9001296","volume":"52","author":"LD Hicks","year":"2009","unstructured":"Hicks LD, Hyatt JL, Stoddard S et al (2009) Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (irinotecan; CPT-11) toxicity. J Med Chem 52:3742\u20133752. https:\/\/doi.org\/10.1021\/jm9001296","journal-title":"J Med Chem"},{"key":"11315_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22362-2","volume":"12","author":"S Iketani","year":"2021","unstructured":"Iketani S, Forouhar F, Liu H et al (2021) Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat Commun 12:1\u201324. https:\/\/doi.org\/10.1038\/s41467-021-22362-2","journal-title":"Nat Commun"},{"key":"11315_CR50","doi-asserted-by":"publisher","first-page":"125444","DOI":"10.1016\/j.ijbiomac.2023.125444","volume":"245","author":"S Mani","year":"2023","unstructured":"Mani S, Kaur A, Jakhar K et al (2023) Targeting DPP4-RBD interactions by sitagliptin and linagliptin delivers a potential host-directed therapy against pan-SARS-CoV-2 infections. Int J Biol Macromol 245:125444. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125444","journal-title":"Int J Biol Macromol"},{"key":"11315_CR51","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1042\/BCJ20210244","volume":"478","author":"CT Lim","year":"2021","unstructured":"Lim CT, Tan KW, Wu M et al (2021) Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. Biochem J 478:2517\u20132531. https:\/\/doi.org\/10.1042\/BCJ20210244","journal-title":"Biochem J"},{"key":"11315_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bib\/bbaa161","volume":"22","author":"Q Bai","year":"2021","unstructured":"Bai Q, Tan S, Xu T et al (2021) MolAICal: a soft tool for 3D drug design of protein targets by artificial intelligence and classical algorithm. Brief Bioinform 22:1\u201312. https:\/\/doi.org\/10.1093\/bib\/bbaa161","journal-title":"Brief Bioinform"},{"key":"11315_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.abb3405","volume":"3405","author":"L Zhang","year":"2020","unstructured":"Zhang L, Daizong L, Xinyuanyuan S et al (2020) Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors. Science 3405:1\u20139. https:\/\/doi.org\/10.1126\/science.abb3405","journal-title":"Science"},{"key":"11315_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13659-024-00486-4","volume":"15","author":"X Gu","year":"2025","unstructured":"Gu X, Zhang X, Zhang X et al (2025) Unveiling the mechanism of action of a novel natural dual inhibitor of SARS-CoV-2 Mpro and PLpro with molecular dynamics simulations. Nat Products Bioprospect 15:3. https:\/\/doi.org\/10.1007\/s13659-024-00486-4","journal-title":"Nat Products Bioprospect"},{"key":"11315_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ardp.202300403","volume":"356","author":"Y Yang","year":"2023","unstructured":"Yang Y, Sun X, Luo L et al (2023) Discovery of novel potent PI3K\/mTOR dual-target inhibitors based on scaffold hopping: design, synthesis, and antiproliferative activity. Arch Pharm (Weinheim) 356:3. https:\/\/doi.org\/10.1002\/ardp.202300403","journal-title":"Arch Pharm (Weinheim)"},{"key":"11315_CR56","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1021\/acschembio.9b00490","volume":"14","author":"Y Tahara","year":"2019","unstructured":"Tahara Y, Kietrys AM, Hebenbrock M et al (2019) Dual inhibitors of 8-oxoguanine surveillance by OGG1 and NUDT1. ACS Chem Biol 14:2606\u20132615. https:\/\/doi.org\/10.1021\/acschembio.9b00490","journal-title":"ACS Chem Biol"},{"key":"11315_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12885-022-10428-3","volume":"23","author":"Y Harada","year":"2023","unstructured":"Harada Y, Sato A, Nakamura H et al (2023) Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. BMC Cancer 23:77. https:\/\/doi.org\/10.1186\/s12885-022-10428-3","journal-title":"BMC Cancer"},{"key":"11315_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2023.2270781","author":"D Zou","year":"2023","unstructured":"Zou D, Liu R, Lv Y et al (2023) Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer\u2019s disease. J Enzyme Inhib Med Chem. https:\/\/doi.org\/10.1080\/14756366.2023.2270781","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11315_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30030491","author":"A Varghese","year":"2025","unstructured":"Varghese A, Liu J, Liu B et al (2025) Analysis of structures of SARS-CoV-2 papain-like protease bound with ligands unveils structural features for inhibiting the enzyme. Molecules. https:\/\/doi.org\/10.3390\/molecules30030491","journal-title":"Molecules"},{"key":"11315_CR60","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1073\/pnas.0510851103","volume":"103","author":"K Ratia","year":"2006","unstructured":"Ratia K, Saikatendu KS, Santarsiero BD et al (2006) Severe acute respiratory syndrome coronavirus papain-like-protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA 103:5717\u20135722. https:\/\/doi.org\/10.1073\/pnas.0510851103","journal-title":"Proc Natl Acad Sci USA"},{"key":"11315_CR61","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","volume":"11","author":"X Gao","year":"2021","unstructured":"Gao X, Qin B, Chen P et al (2021) Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B 11:237\u2013245. https:\/\/doi.org\/10.1016\/j.apsb.2020.08.014","journal-title":"Acta Pharm Sin B"},{"key":"11315_CR62","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.str.2024.08.005","volume":"32","author":"W Cui","year":"2024","unstructured":"Cui W, Duan Y, Gao Y et al (2024) Structural review of SARS-CoV-2 antiviral targets. Structure 32:1301\u20131321. https:\/\/doi.org\/10.1016\/j.str.2024.08.005","journal-title":"Structure"},{"key":"11315_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2020.00174","volume":"7","author":"YK Bosken","year":"2020","unstructured":"Bosken YK, Cholko T, Lou Y-C et al (2020) Insights into dynamics of inhibitor and ubiquitin-like protein binding in SARS-CoV-2 papain-like protease. Front Mol Biosci 7:1\u201314. https:\/\/doi.org\/10.3389\/fmolb.2020.00174","journal-title":"Front Mol Biosci"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11315-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T11:33:06Z","timestamp":1779535986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11315-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["11315"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11315-2","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,7]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"No human or animal subjects were involved in this study; therefore, no ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}